, but it inhibits Pi transport with very low affinity (K i 2.6 mM) 2 because these cells only express type III Na/Pi cotransporters. 2 Therefore, the mechanism of vascular prevention by PFA should be different from that of Pi-transport inhibition, as we have described recently (Figure 1) .
In a recent study, 4 we clarified the mechanism whereby PFA prevents VSMC calcification. We showed that PFA inhibits calcium-phosphate deposition in a process that is independent of any cell activity or metabolism and that is similar to the physicochemical mechanism of bisphosphonate drugs and pyrophosphate. 4 This rationale was already proposed decades ago by several researchers, and it also coincides with a recent study by Prof. O'Neill's group. 5 Therefore, the use of PFA as a tool to inhibit Pi transport in vascular calcification research should be avoided, because the concentrations of PFA that significantly inhibit Pi transport in VSMC also exhibit cytotoxic side effects. 4 1. Villa-Bellosta R, Sorribas V. Role of rat sodium/phosphate cotransporters in the cell membrane transport of arsenate. Despite the fact that phosphonoformic acid (PFA) is a very weak inhibitor of the type III phosphate transporters present in vascular smooth muscle, its inhibition of calcification in cultured vascular smooth muscle cells (VSMCs) has been used to support a role for phosphate transport in vascular calcification. 1 However, as pointed out by Villa-Bellosta and Sorribas, 2 PFA is also a nonhydrolyzable analog of pyrophosphate (PPi). PPi is a potent, direct inhibitor of hydroxyapatite crystal formation that inhibits vascular calcification in vitro and in vivo, a property shared by a number of analogs, including bisphosphonates. 3 Not surprisingly, Villa-Bellosta and Sorribas have shown that this is also the mechanism by which PFA inhibits calcification in VSMCs. This is yet another example of a 'specific' inhibitor that, like most 'specific' inhibitors, is not specific.
Subsequent studies using antisense RNA directed against Pit-1 have also shown inhibition of calcification in VSMCs, 4 supporting a role for phosphate transport. However, caution must also be exercised in interpreting these results because VSMCs undergo substantial phenotypic changes in culture and lack the normal elastin matrix, which is the site of medial calcification in vivo. Using the whole aorta culture method, we have been unable to duplicate many of the findings in VSMCs related to medial calcification. Thus, the intriguing and potentially important role of phosphate transporters in vascular calcification, although widely cited, remains to be proven in a relevant model. 
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